These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 15355889)

  • 1. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2.
    Gennari R; Menard S; Fagnoni F; Ponchio L; Scelsi M; Tagliabue E; Castiglioni F; Villani L; Magalotti C; Gibelli N; Oliviero B; Ballardini B; Da Prada G; Zambelli A; Costa A
    Clin Cancer Res; 2004 Sep; 10(17):5650-5. PubMed ID: 15355889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2.
    Varchetta S; Gibelli N; Oliviero B; Nardini E; Gennari R; Gatti G; Silva LS; Villani L; Tagliabue E; Ménard S; Costa A; Fagnoni FF
    Cancer Res; 2007 Dec; 67(24):11991-9. PubMed ID: 18089830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
    Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):78-83. PubMed ID: 10482197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
    Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I
    Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
    Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
    J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.
    Barok M; Tanner M; Köninki K; Isola J
    Cancer Lett; 2011 Jul; 306(2):171-9. PubMed ID: 21458915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
    Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
    Goldenberg MM
    Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study.
    Repka T; Chiorean EG; Gay J; Herwig KE; Kohl VK; Yee D; Miller JS
    Clin Cancer Res; 2003 Jul; 9(7):2440-6. PubMed ID: 12855616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity and resistance of trastuzumab according to different clinical settings.
    Tagliabue E; Campiglio M; Pupa SM; Ménard S; Balsari A
    Cancer Treat Rev; 2012 May; 38(3):212-7. PubMed ID: 21726959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
    Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
    J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer.
    Chang HR
    Cancer; 2010 Jun; 116(12):2856-67. PubMed ID: 20564392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.
    Parihar R; Nadella P; Lewis A; Jensen R; De Hoff C; Dierksheide JE; VanBuskirk AM; Magro CM; Young DC; Shapiro CL; Carson WE
    Clin Cancer Res; 2004 Aug; 10(15):5027-37. PubMed ID: 15297404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.
    Harris LN; You F; Schnitt SJ; Witkiewicz A; Lu X; Sgroi D; Ryan PD; Come SE; Burstein HJ; Lesnikoski BA; Kamma M; Friedman PN; Gelman R; Iglehart JD; Winer EP
    Clin Cancer Res; 2007 Feb; 13(4):1198-207. PubMed ID: 17317830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer.
    Horiguchi J; Oyama T; Koibuchi Y; Yokoe T; Takata D; Ikeda F; Nagaoka H; Rokutanda N; Nagaoka R; Ishikawa Y; Odawara H; Kikuchi M; Sato A; Iino Y; Takeyoshi I
    Anticancer Res; 2009 Feb; 29(2):517-24. PubMed ID: 19331197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
    Sperinde J; Jin X; Banerjee J; Penuel E; Saha A; Diedrich G; Huang W; Leitzel K; Weidler J; Ali SM; Fuchs EM; Singer CF; Köstler WJ; Bates M; Parry G; Winslow J; Lipton A
    Clin Cancer Res; 2010 Aug; 16(16):4226-35. PubMed ID: 20664024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
    Guarneri V; Barbieri E; Dieci MV; Piacentini F; Conte P
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S62-6. PubMed ID: 21129613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
    Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
    Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.